209 related articles for article (PubMed ID: 35737026)
1. Comparative Pharmacodynamics of Three Different Botulinum Toxin Type A Preparations following Repeated Intramuscular Administration in Mice.
Byun J; Kwak S; Kwon JH; Shin M; Lee DK; Rhee CH; Kang WH; Oh JW; Cruz DJM
Toxins (Basel); 2022 May; 14(6):. PubMed ID: 35737026
[TBL] [Abstract][Full Text] [Related]
2. The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis.
Broide RS; Rubino J; Nicholson GS; Ardila MC; Brown MS; Aoki KR; Francis J
Toxicon; 2013 Sep; 71():18-24. PubMed ID: 23707612
[TBL] [Abstract][Full Text] [Related]
3. Comparative Pharmacodynamics Study of 3 Different Botulinum Toxin Type A Preparations in Mice.
Kwak S; Kang WH; Rhee CH; Yang GH; Cruz DJM
Dermatol Surg; 2020 Dec; 46(12):e132-e138. PubMed ID: 32251006
[TBL] [Abstract][Full Text] [Related]
4. AbobotulinumtoxinA (Dysport
Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K
Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641
[TBL] [Abstract][Full Text] [Related]
5. OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays.
Rupp D; Nicholson G; Canty D; Wang J; Rhéaume C; Le L; Steward LE; Washburn M; Jacky BP; Broide RS; Philipp-Dormston WG; Brin MF; Brideau-Andersen A
Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32545832
[TBL] [Abstract][Full Text] [Related]
6. Ouabain exacerbates botulinum neurotoxin-induced muscle paralysis via progression of muscle atrophy in mice.
Fujikawa R; Muroi Y; Unno T; Ishii T
J Toxicol Sci; 2010 Dec; 35(6):795-805. PubMed ID: 21139329
[TBL] [Abstract][Full Text] [Related]
7. How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: Study in juvenile rats.
Shen J; Ma J; Lee C; Smith BP; Smith TL; Tan KH; Koman LA
J Orthop Res; 2006 May; 24(5):1128-35. PubMed ID: 16602109
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations.
Brown M; Nicholson G; Ardila MC; Satorius A; Broide RS; Clarke K; Hunt T; Francis J
J Neural Transm (Vienna); 2013 Feb; 120(2):291-8. PubMed ID: 22842675
[TBL] [Abstract][Full Text] [Related]
9. The Effects of Botulinum Toxin Injections on Spasticity and Motor Performance in Chronic Stroke with Spastic Hemiplegia.
Chen YT; Zhang C; Liu Y; Magat E; Verduzco-Gutierrez M; Francisco GE; Zhou P; Zhang Y; Li S
Toxins (Basel); 2020 Jul; 12(8):. PubMed ID: 32751970
[TBL] [Abstract][Full Text] [Related]
10. [Impact of integrated upper limb spasticity management including repeat botulinum toxin type A (BoNT-A) injections on patient-centred goal attainment in real-life practice: results from the prospective, observational Upper Limb International Spasticity cohort study (ULIS-III) in a Russian subpopulation].
Khat'kova SE; Baikova A; Maisonobe P; Khasanova DR
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(11):39-48. PubMed ID: 34932284
[TBL] [Abstract][Full Text] [Related]
11. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.
Roger Aoki K
Toxicon; 2002 Jul; 40(7):923-8. PubMed ID: 12076646
[TBL] [Abstract][Full Text] [Related]
12. Dramatic changes in muscle contractile and structural properties after 2 botulinum toxin injections.
Minamoto VB; Suzuki KP; Bremner SN; Lieber RL; Ward SR
Muscle Nerve; 2015 Oct; 52(4):649-57. PubMed ID: 25598004
[TBL] [Abstract][Full Text] [Related]
13. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects.
Mitsikostas DD; Dekundy A; Hanschmann A; Althaus M; Scheschonka A; Pagan F; Jankovic J
Curr Med Res Opin; 2021 Oct; 37(10):1761-1768. PubMed ID: 34384301
[TBL] [Abstract][Full Text] [Related]
14. A pharmacodynamic comparison study of different botulinum toxin type A preparations.
Kim SB; Ban B; Jung KS; Yang GH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):150-4. PubMed ID: 23301818
[TBL] [Abstract][Full Text] [Related]
15. Time course response after single injection of botulinum toxin to treat spasticity after stroke: Systematic review with pharmacodynamic model-based meta-analysis.
Ojardias E; Ollier E; Lafaie L; Celarier T; Giraux P; Bertoletti L
Ann Phys Rehabil Med; 2022 May; 65(3):101579. PubMed ID: 34634514
[TBL] [Abstract][Full Text] [Related]
16. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
Frevert J
Drugs R D; 2010; 10(2):67-73. PubMed ID: 20698714
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal assessment of gait quality in children with bilateral cerebral palsy following repeated lower limb intramuscular Botulinum toxin-A injections.
Read FA; Boyd RN; Barber LA
Res Dev Disabil; 2017 Sep; 68():35-41. PubMed ID: 28735160
[TBL] [Abstract][Full Text] [Related]
18. The use of the dynamic weight bearing test to assess the effects of acute, intramuscularly administered botulinum neurotoxin type A1 in rats.
Cornet S; Périer C; Wagner S; Andriambeloson E; Pouzet B; Kalinichev M
Toxicon X; 2020 Sep; 7():100041. PubMed ID: 32550595
[TBL] [Abstract][Full Text] [Related]
19. In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.
Kutschenko A; Manig A; Reinert MC; Mönnich A; Liebetanz D
Neurosci Lett; 2016 Aug; 627():216-21. PubMed ID: 27268041
[TBL] [Abstract][Full Text] [Related]
20. Botulinum Neurotoxin A injections influence stretching of the gastrocnemius muscle-tendon unit in an animal model.
Haubruck P; Mannava S; Plate JF; Callahan MF; Wiggins WF; Schmidmaier G; Tuohy CJ; Saul KR; Smith TL
Toxins (Basel); 2012 Aug; 4(8):605-19. PubMed ID: 23012650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
